GSK961081
Sponsors
GlaxoSmithKline, Theravance Biopharma
Conditions
Pulmonary Disease, Chronic Obstructive
Phase 1
Succinate Salt Version of GSK961081 for Healthy Volunteers
CompletedNCT00550225
Start: 2007-11-29End: 2008-01-08Updated: 2021-10-06
A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers
CompletedNCT00687700
Start: 2008-03-10End: 2008-05-27Updated: 2021-10-06
Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination
CompletedNCT02064504
Start: 2014-02-19End: 2014-05-20Updated: 2017-05-15
Phase 2
A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients
CompletedNCT00478738
Start: 2007-06-30End: 2008-05-31Updated: 2017-02-02
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01319019
Start: 2010-12-31End: 2011-09-30Updated: 2016-12-01